CardioTech to develop treatment for congestive heart failure using antithrombogenic coating technology

By Lisa Kerner

Charlotte, N.C., June 28 - CardioTech International, Inc. said it will develop innovative medical solutions for the treatment of congestive heart failure at its Gish Biomedical laboratories using proprietary antithrombogenic coating technology.

"We are excited about the $1.5 billion potential worldwide market opportunity to leverage our existing technology and proprietary coating to introduce a new product to treat congestive heart failure patients," said Michael Adams, vice president of regulatory affairs and business development, in a news release.

Congestive heart failure causes an inability to eliminate excess fluid from the body. Current treatment includes oral and intravenous use of diuretics, or removal of the fluid in a procedure similar to dialysis, the company said.

Located in Wilmington, Mass., medical device company CardioTech develops, manufactures and sells advanced products for the treatment of cardiovascular and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.